Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring Nov 21 | 2018Dexcom and Verily Update Agreement, Focus on T2DM MarketPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 20 | 2018Onduo Free Promotional Program; Insulet Dash Meets ISO StandardsPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 20 | 2018Medtronic CY Q3 '18 (FY Q2 '19) Earnings UpdatePurchase Blast$599
Posted in: Glucose Monitoring Nov 19 | 2018Verily/Novartis Halts Glucose Sensing Contact Lens DevelopmentPurchase Blast$599
Posted in: Glucagon Nov 15 | 2018Zealand Q3 '18 Earnings; Xeris Initiates New Ph3 Study vs. GlucaGenPurchase Blast
Free
Posted in: Other Nov 14 | 2018Amarin’s REDUCE-IT: Winners, Losers, and Suitors AnalysisAccess Free Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 11 | 2018Thoughts on the Regulatory Environment in DiabetesPurchase Blast$599
Posted in: SGLT2i Nov 11 | 2018DECLARE Disappoints, Yet Creates Many ImplicationsPurchase Blast$599
Posted in: Glucose Monitoring Nov 08 | 2018Senseonics Q3 '18 Earnings Update; Abbott FreeStyle Link Now AvailablePurchase Blast$599
Posted in: DPP-IVi, GLP-1RA, SGLT2i Nov 08 | 2018Farxiga T1DM US Filing in Q4 '18; AZ Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: Insulin Delivery Nov 07 | 2018Insulet Partners with Samsung for Smartphone Pump ControlPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 06 | 2018New Dexcom Approvals; Dexcom and BD Q3 '18 Earnings UpdatesPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, SGLT2i Nov 06 | 2018REWIND Safety Issue? Lilly Q3 '18 Earnings UpdatePurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA Nov 05 | 2018Positive Trulicity CVOT Creates Many Market ImplicationsPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
